STUDIES

Study #1: COVID-19 vaccine effectiveness against hospitalisation

This study uses a multi-country hospital-based test negative case control design. Patient recruitment was initiated in September 2021 and by April 15th, over 13,270 patients were recruited across 21 hospitals in 5 European countries.

The study was initiated on request by AstraZeneca and Janssen and was later joined by Novavax, Valneva and Pfizer to fulfil regulatory commitments. The data collection is still ongoing.

The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe”.

Hospitals recruiting for the COVID-19 Vaccine Effectiveness study

Study #2: Respiratory surveillance study

This is a multi-country hospital-based study will monitor viral respiratory infections in adults hospitalised for severe acute respiratory infection (SARI) will starting in summer 2024.

The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe”.

Study #3: Respiratory Syncytial Virus (RSV) vaccine effectiveness against hospitalisation

This study uses a multi-country hospital-based test negative case control design. This study is in setup phase and will start in fall 2024.

The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe”.